看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
& ]8 z: K+ \2 ~
$ x# K) u# U. ^1 y5 h8 X# f, s# R4 r( \( _) ^
Currently available feasibility data for possible combination strategies. 2 n! C6 A m6 J5 O' h0 X
————————————————————————————————
. Q$ ~% ?6 a' F3 n, l8 f$ PCombination Feasibility according to preliminary data 9 @6 L6 u ^6 B
——————————————————————————————————; [/ @0 e7 L N
Bevacizumab + sorafenib Yes, reduced dose
+ ^: I( _8 o' T( r4 v& Z w2 CBevacizumab + sunitinib† No + r5 {$ p) o8 U! t- m
Bevacizumab + temsirolimus Yes $ p! @$ x$ R7 b9 |) C5 \; n
Bevacizumab + everolimus Yes
1 L r& T2 |: Y8 j& a5 bSorafenib + sunitinib ?
1 l r! K' J% w' YSorafenib + temsirolimus Yes, reduced dose 0 f. a% l) [6 s8 `! r% M; b
Sorafenib + everolimus Yes, reduced dose
; K1 Z7 H2 u [1 Q# I& SSunitinib + temsirolimus† No
! o% M1 n" s! h- e2 z2 r @5 sSunitinib + everolimus ?
( I7 b' n$ M. N+ r$ f. b2 [Temsirolimus + everolimus ? m9 b& z" m$ V* W7 @
————————————————————
* K/ \$ E! T4 M, D4 L1 a. F# H†Led to US FDA warning.
1 Q) Q9 _- L0 ~?: As yet unattempted combination. O- u2 K+ Z- Z
|
显身卡
2 I; L% f& s4 P2 `8 l) N5 z
